<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908465</url>
  </required_header>
  <id_info>
    <org_study_id>S55485</org_study_id>
    <nct_id>NCT01908465</nct_id>
  </id_info>
  <brief_title>Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial</brief_title>
  <official_title>Peripheral Histamine 1 Receptor Blockade in IBS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the
      H1-receptor antagonist ebastine.

      Design:

      Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment
      with ebastine 20mg once daily or placebo (1:1 randomization).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of treatment on global symptom relief (of IBS complaints)</measure>
    <time_frame>after 12 weeks treatment</time_frame>
    <description>By mean of weekly GSRS (Gastrointestinal Symptom Rating Scale )questionnaires and weekly &quot;SGA (Subject's Global Assessment) of relief&quot; and &quot;SGA of Abdominal Pain and Discomfort&quot; questionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment on stool consistency and frequency and other common IBS associated complaints (flatulence, urgency,...)</measure>
    <time_frame>fter 12 weeks treatment</time_frame>
    <description>By mean of weekly questionnaires</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of treatment on quality of life</measure>
    <time_frame>after 12 weeks treatment</time_frame>
    <description>By mean of 'Quality of life&quot; questionnaire (completed at the end (after 14 weeks) and the start of the study and after 8 and 12 weeks of treatment)</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of treatment on inflammatory mediators/metabolites in urine</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>By metabolic profiling in urine samples before and after treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Irritable Bowel Syndrome (IBS)</condition>
  <arm_group>
    <arm_group_label>Ebastine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ebastine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ebastine</intervention_name>
    <arm_group_label>Ebastine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Irritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed
             form

          -  age 18-65 years

        Exclusion Criteria:

          -  IBS subtype with constipation

          -  medication: antidepressants or H1-receptor antagonists

          -  pregnancy, breast feeding

          -  co-morbidity: severe kidney- and/or liver disease or other gastrointestinal diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Boeckxstaens, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Leuven and Universitary Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lien Beullens, MSc</last_name>
    <phone>0032-16-341943</phone>
    <email>lien.beullens@kuleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dafne Balemans, MSc</last_name>
    <phone>0032-16-330158</phone>
    <email>dafne.balemans@med.kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom Moreels, M.D.</last_name>
      <phone>+32 3 821 33 24</phone>
      <email>tom.moreels@uza.be</email>
    </contact>
    <investigator>
      <last_name>Tom Moreels, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZOL (Ziekenhuis Oost-Limburg)</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Caenepeel, M.D.</last_name>
      <phone>+32 8 32 65 13</phone>
      <email>philip.caenepeel@zol.be</email>
    </contact>
    <investigator>
      <last_name>Philip Caenepeel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Van de Moortele</last_name>
      <phone>+32 9 332 68 54</phone>
      <email>Sabine.VandeMoortele@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>MuriÃ«l Fouquet</last_name>
      <phone>+32 9 332 33 36</phone>
      <email>Muriel.Fouquet@uzgent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Danny De Looze, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Elizabeth Zottegem</name>
      <address>
        <city>Zottegem</city>
        <state>Oost-Vlaanderen</state>
        <zip>9620</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Vanslembrouck, M.D.</last_name>
      <phone>+32 93 64 83 41</phone>
      <email>inge.vanslembrouck@sezz.be</email>
    </contact>
    <contact_backup>
      <last_name>Inge Vanslembrouck, M.D.</last_name>
      <phone>+32 93 64 83 43</phone>
      <email>inge.vanslembrouck@sezz.be</email>
    </contact_backup>
    <investigator>
      <last_name>Sebastien Kindt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lien Beullens, MSc</last_name>
      <phone>0032-16-341943</phone>
      <email>lien.beullens@kuleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Dafne Balemans</last_name>
      <phone>0032-16-330158</phone>
      <email>dafne.balemans@med.kuleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Guy Boeckxstaens, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas Brugge</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Nevens</last_name>
      <phone>+32 50 36 57 11</phone>
      <email>hilde.nevens@stlucas.be</email>
    </contact>
    <contact_backup>
      <last_name>Joris Arts, M.D.</last_name>
      <phone>+32 50 36 51 55</phone>
      <email>jar@stlucas.be</email>
    </contact_backup>
    <investigator>
      <last_name>Joris Arts, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.G. Baten, M.D.</last_name>
      <phone>0031 88 005 6671</phone>
    </contact>
    <contact_backup>
      <last_name>D. Hirsch, M.D.</last_name>
      <email>DHirsch@Rijnstate.nl</email>
    </contact_backup>
    <investigator>
      <last_name>D. Hirsch, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Limburg</state>
        <zip>7500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anita Westerhof</last_name>
      <phone>0031(53)4877511</phone>
    </contact>
    <contact_backup>
      <last_name>J. Kolkman, M.D.</last_name>
      <phone>0031 (53) 487 24 10</phone>
      <email>j.kolkman@mst.nll</email>
    </contact_backup>
    <investigator>
      <last_name>J. Kolkman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samefko Ludidi</last_name>
    </contact>
    <contact_backup>
      <last_name>A. Masclee, M.D.</last_name>
      <email>a.masclee@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>A. Masclee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Lucas Andreas Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1061</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sjoerd Kuiken, M.D.</last_name>
      <email>s.kuiken@slaz.nl</email>
    </contact>
    <investigator>
      <last_name>Sjoerd Kuiken, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A.J. Bredenoord, M.D.</last_name>
      <email>A.J.Bredenoord@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>A.J. Bredenoord, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenuizen Blaricum/Hilversum</name>
      <address>
        <city>Hilversum/Blaricum</city>
        <state>Noord-Holland</state>
        <zip>1213/1261</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Verloop</last_name>
      <phone>0031 (35) 539 19 25</phone>
      <email>kverloop@tergooiziekenhuizen.nl</email>
    </contact>
    <contact_backup>
      <last_name>B. van den Elzen, M.D.</last_name>
      <email>BvandenElzen@tergooiziekenhuizen.nl</email>
    </contact_backup>
    <investigator>
      <last_name>B. van den Elzen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Guy Boeckxstaens</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
    <mesh_term>Ebastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

